Clinical Trial Update: Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

View source ↗

Summary

Prospective study evaluating the Prosigna genomic assay for informing neoadjuvant treatment decisions in women with HR+/HER2- breast cancer; the trial status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Status: ACTIVE_NOT_RECRUITING